8-KOther EventsExhibits & Filings

JOHNSON & JOHNSON 8-K Report, Corporate Update (Apr 15, 2011)

Filed April 15, 2011For Securities:JNJ

Summary

Johnson & Johnson (JNJ) has reached an agreement with Merck & Co., Inc. to amend the distribution rights for REMICADE® (infliximab) and SIMPONI® (golimumab), key treatments for chronic inflammatory diseases. This resolves a significant arbitration proceeding initiated by JNJ in May 2009, stemming from the proposed merger between Merck and Schering-Plough, which had impacted their existing distribution agreement. The resolution of this arbitration is a positive development for JNJ investors, providing clarity on the future distribution and commercialization of these important biologic drugs. While the specific financial terms of the amended agreement are detailed in a separate press release, the conclusion of this legal dispute removes a layer of uncertainty and allows both companies to move forward with their respective roles in marketing these therapies. Investors should look to the attached press releases for further details on the financial implications.

Key Highlights

  • 1Agreement reached with Merck & Co., Inc. to amend distribution rights for REMICADE® and SIMPONI®.
  • 2Resolves arbitration proceeding initiated by Johnson & Johnson in May 2009.
  • 3Arbitration was initiated due to concerns arising from the proposed merger between Merck and Schering-Plough affecting distribution agreements.
  • 4REMICADE® and SIMPONI® are treatments for chronic inflammatory diseases like rheumatoid arthritis.
  • 5The agreement brings clarity and reduces uncertainty regarding the commercialization of these key drugs.
  • 6Detailed financial terms of the amended agreement are available in a separate JNJ press release (Exhibit 99.2).

Frequently Asked Questions

REMICADE® and SIMPONI® are biologic drugs used to treat chronic inflammatory diseases such as rheumatoid arthritis. They represent significant products within Johnson & Johnson's pharmaceutical portfolio, contributing to revenue and market share in the immunology sector.

The arbitration proceeding was initiated by Johnson & Johnson in May 2009. It sought a ruling on the distribution agreement for REMICADE® and SIMPONI® after Merck announced its proposed merger with Schering-Plough, which JNJ believed could impact their existing arrangements.

While the 8-K filing itself doesn't detail the financial impact, it mentions a separate press release (Exhibit 99.2) that discusses the financial details of the amended agreement. Investors should refer to that document for specific information on revenue, profit sharing, or any other financial implications resulting from the revised distribution rights.

The filing indicates an amendment to 'distribution rights.' It is likely that the core responsibilities for manufacturing and marketing remain largely the same, but the specific territorial or commercial rights for distribution have been renegotiated or clarified between Johnson & Johnson (and its subsidiary Centocor Ortho Biotech Inc.) and Merck & Co., Inc.